Therapeutic Antibody

Therapeutic Antibody designates monoclonal antibodies or antibody derivatives engineered for medical applications, harnessing immune recognition specificity and effector functions to treat diseases through mechanisms including blocking pathological interactions, targeting cells for immune destruction, delivering cytotoxic payloads, or modulating immune responses. These protein therapeutics represent the fastest-growing pharmaceutical segment, with dozens of approved products and extensive pipelines addressing cancer, autoimmune diseases, infectious diseases, and other conditions.

The biopharmaceutical industry has established therapeutic antibodies as major drug class through decades of development advancing from mouse antibodies to humanised and fully human versions eliminating immunogenicity concerns. Mechanisms include receptor antagonism blocking ligand binding, cell depletion through antibody-dependent cellular cytotoxicity or complement activation, immune checkpoint modulation releasing anti-tumour immunity, neutralisation of pathogens or toxins, and targeted payload delivery. Discovery employs hybridoma technology, phage display, transgenic mice, or single B-cell cloning identifying antigen-specific antibodies. Manufacturing uses mammalian cell culture, typically CHO cells, producing properly folded, glycosylated proteins. Pharmacokinetics exhibit extended half-lives through FcRn recycling enabling infrequent dosing. Innovation continues through novel formats, optimised properties, combination approaches, and expanded applications. As technology advances enabling complex engineering and understanding deepens regarding optimal properties, therapeutic antibodies continue dominating biopharmaceutical development.